[Effects of a selective cyclooxygenase 2 inhibitor celecoxib on the proliferation and apoptosis of human prostate cancer cell line PC-3].
OBJECTIVE
To investigate the anti-tumor effect of celecoxib on human prostate cancer cell line PC-3 in vitroby observing its effects on the proliferation and apoptosis of PC-3 cells.


METHODS
The effects of Celecoxib on the proliferation of PC-3 cells were observed by MTT assay, erosion trace test and Transwell-chamber chemotaxis assay, and their apoptosis detected by Annexin V/FITC fluorescent staining and flow cytometry.


RESULTS
With the increasing concentration and exposure time, Celecoxib exhibited an increased rate of inhibition on PC-3 cells in a dose- and time-dependent manner (P < 0.05). Compared with the controls, the migration distance of the PC-3 cells and the number of the PC-3 cells that invaded the inferior chamber were significantly decreased in the 100 gm/L Celecoxib group (P < 0.05). Celecoxib induced the apoptosis of PC-3 cells and, at 100 microm/L, significantly increased the percentage of PC-3 cells in the G0/G1 phase but decreased it in the S phase as compared with the control group (P < 0.05).


CONCLUSIONS
Celecoxib inhibits the proliferation and induces the apoptosis of PC-3 cells in vitro, which, as a new therapeutic for prostate cancer, well deserves further investigation.
Xu
Song
S
Department of Urology, Nanjing School of Clinical Medicine, the Second Military Medical University/Nanjing General Hospital of Nanjing Military Command, PLA, Nanjing, Jiangsu 210002, China.
Zhou
Wen-quan
WQ
Zhang
Zheng-yu
ZY
Ge
Jing-ping
JP
Gao
Jian-ping
JP
D017209:Apoptosis / Q000187:drug effects*; D000068579:Celecoxib; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology / Q000503:physiopathology; D011720:Pyrazoles / Q000494:pharmacology*; D013449:Sulfonamides / Q000494:pharmacology*; D013997:Time Factors
D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib